Medical cannabis may play a role in managing fibromyalgia and related symptoms of depression and anxiety, according to a peer-reviewed study published in the American Journal of Endocannabinoid Medicine. Three-fourths of the more than 800 patients assessed saw a significant decrease in their self-reported illness severity, according to the study, which was led by researchers at Harvest Medicine, a subsidiary of MediPharm Labs Corp. MEDIF. Fibromyalgia is a chronic condition that affects about 4 million U.S. adults and causes musculoskeletal pain, fatigue and mood issues. Most patients in the study used CBD oil. Roughly half of the patients with severe anxiety or depression saw a reduction in those symptoms. MediPharm specializes in developing and manufacturing cannabis concentrates and active pharmaceutical ingredients. MediPharm stock was unchanged premarket on Thursday and has gained 15.6% in the year to date, while the S&P 500 SPX has gained 17.6%.

Market Pulse Stories are Rapid-fire, short news bursts on stocks and markets as they move. Visit for more information on this news.

A note to our visitors

This website has updated its privacy policy in compliance with changes to European Union data protection law, for all members globally. We’ve also updated our Privacy Policy to give you more information about your rights and responsibilities with respect to your privacy and personal information. Please read this to review the updates about which cookies we use and what information we collect on our site. By continuing to use this site, you are agreeing to our updated privacy policy.